Blood sugar fell in adults with type 1 diabetes and excess weight
A measure of longer-term blood sugar fell 0.4 to 0.6 percentage points with acmopatide versus 0.3 points with placebo over 16 weeks.
Double-blind, placebo-controlled, multicenter
Limit: The 16-week trial cannot address lasting benefits or uncommon risks
Stake: Carmot Therapeutics, which develops ct-868, funded the study.
Edited by Boris Djordjevic · AgingResearch.News
In a phase 2 randomized trial, 111 adults with type 1 diabetes and overweight or obesity received daily injections of acmopatide or placebo for 16 weeks. Neither participants nor researchers knew who received which injections. Acmopatide doses were 1.8, 4.1 or 6.6 mg.
Researchers measured HbA1c, a measure of average blood sugar over recent months. It fell by 0.4 to 0.6 percentage points with acmopatide and 0.3 points with placebo. The 4.1 mg dose lowered it by 0.3 percentage points more than placebo. Body weight fell by 3.3% to 6.7% with acmopatide, versus a 0.3% rise with placebo. Reported adverse events mainly involved digestive symptoms. No diabetic ketoacidosis, a dangerous buildup of acids in the blood, or severe low-blood-sugar episodes occurred.
Why it matters
For people aging with type 1 diabetes, a key question is whether improvements in blood sugar and weight translate into lasting health benefits.
Caveats
This small, 16-week phase 2 trial cannot establish long-term benefits or uncommon risks. The findings concern adults with type 1 diabetes and overweight or obesity, not children or adults without excess weight.
The paper
University of North Carolina at Chapel Hill
Diabetes Care, Oct 28, 2026
